肿瘤细胞治疗研究
ALL SOURCES
Next-generation antibody-based therapeutics in cancer: antibody-drug conjugates bispecific antibodies across hematologic malignancies and solid tumors
肿瘤学的治疗范式正在经历由抗体药物偶联物（ADC）和双特异性抗体（bsAb）驱动的深刻变革。
IDR-induced CAR condensation improves the cytotoxicity of CAR-Ts against low-antigen cancers.
我们的工作表明，IDR 是通过诱导生物分子凝聚来改善 CAR-T 功能的新工具集。
Advances and challenges in CAR-T cell therapy for head and neck squamous cell carcinoma.
头颈部鳞状细胞癌（HNSCC）仍是最具侵袭性的恶性肿瘤之一，治疗选择有限，尤其是在复发和转移性病例中。
Advances in CAR-T therapy for central nervous system tumors.
CAR-T 细胞疗法在中枢神经系统肿瘤中的应用已取得显著进展；
CAR T cells: engineered immune cells to treat brain cancers and beyond.
恶性脑肿瘤属于治疗难度最大的恶性肿瘤类型。
Immunogenetic Metabolomics Reveals Key Enzymes That Modulate CAR T-cell Metabolism and Function.
这些数据共同揭示了对 CAR T 细胞代谢重编程的系统性认识，并揭示了改进 CAR T 细胞疗法的潜在靶点。
A CD19-Anti-ErbB2 scFv Engager Protein Enables CD19-Specific CAR T Cells to Eradicate ErbB2(+) Solid Cancer.
CD19特异性CAR T细胞治疗白血病/淋巴瘤的疗效，至少部分依赖于特定CAR的独特性质以及健康B细胞的存在，后者通过反复刺激增强靶细胞裂解和细胞因子分泌。
Chimeric antigen receptor clustering via cysteines enhances T-cell efficacy against tumor.
嵌合抗原受体（CAR）T细胞疗法在血液系统恶性肿瘤中取得了巨大成功。
A Bibliometric and Knowledge-Map Analysis of CAR-T Cells From 2009 to 2021.
作为一种具有巨大潜力和临床应用前景的抗肿瘤疗法，CAR-T细胞疗法仍处于快速发展阶段。CAR-T细胞相关领域在未来仍将是研究热点。
A novel chimeric antigen receptor (CAR) system using an exogenous protease, in which activation of T cells is controlled by expression patterns of cel
抗 CD19 嵌合抗原受体（CAR）T 细胞疗法治疗难治性 B 细胞恶性肿瘤显示出优异的治疗效果。
MEMBER ACCOUNT
登录成功会直接打开下一页。
